BioAtla (NASDAQ:BCAB) Given “Market Outperform” Rating at JMP Securities

JMP Securities restated their market outperform rating on shares of BioAtla (NASDAQ:BCAB) in a report issued on Monday, Benzinga reports. JMP Securities currently has a $5.00 price objective on the stock.

BioAtla Trading Up 4.8 %

NASDAQ BCAB opened at $1.74 on Monday. BioAtla has a 12 month low of $1.14 and a 12 month high of $4.02. The company has a market capitalization of $83.72 million, a PE ratio of -0.70 and a beta of 1.06. The stock has a 50-day simple moving average of $1.73 and a 200 day simple moving average of $2.13.

BioAtla (NASDAQ:BCAB) last announced its quarterly earnings results on Thursday, August 8th. The company reported ($0.44) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.45) by $0.01. During the same quarter last year, the company earned ($0.75) earnings per share. As a group, sell-side analysts predict that BioAtla will post -1.51 earnings per share for the current fiscal year.

Hedge Funds Weigh In On BioAtla

Institutional investors and hedge funds have recently made changes to their positions in the company. Ground Swell Capital LLC bought a new position in BioAtla during the second quarter worth about $33,000. Valmark Advisers Inc. acquired a new stake in shares of BioAtla during the second quarter worth about $34,000. Rinkey Investments bought a new position in shares of BioAtla during the 2nd quarter valued at about $35,000. Price T Rowe Associates Inc. MD acquired a new position in shares of BioAtla in the 1st quarter valued at approximately $45,000. Finally, American Century Companies Inc. increased its stake in BioAtla by 36.1% during the 2nd quarter. American Century Companies Inc. now owns 43,391 shares of the company’s stock worth $59,000 after purchasing an additional 11,503 shares in the last quarter. Institutional investors and hedge funds own 77.23% of the company’s stock.

BioAtla Company Profile

BioAtla, Inc, a clinical-stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. The company's lead clinical stage product candidates include mecbotamab vedotin (BA3011), a conditionally active biologic (CAB) antibody-drug conjugate (ADC), which is in Phase II clinical trial for treating undifferentiated pleomorphic sarcoma and non-small cell lung cancer (NSCLC); and ozuriftabmab vedotin (BA3021), a CAB ADC that is in Phase II clinical trial for the treatment of melanoma and squamous cell cancer of the head and neck.